Vein access device effective in early study:
This article was originally published in Clinica
An implantable device which provides access to the veins of haemodialysis patients has worked well in a preliminary study of patients at the Austin Diagnostic Center in Texas. The LifeSite device, a stainless steel and titanium alloy valve implanted just under the skin, was developed by Topsfield, Massachusetts-based VascA. According to the results of the study, it allowed increased blood flow and was free from thrombosis in all ten patients. The device, which is already sold in Canada and Europe, is designed as an alternative to fistulas, synthetic grafts and dialysis catheters.
You may also be interested in...
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.
US FDA’s latest effort to provide guidance for consumers on pharmacogenomics tests underscores the challenges the agency faces in the absence of a clear regulatory framework for lab-developed tests – and with no easy mechanism to update labels for off-patent drugs.